NCT01576731View on ClinicalTrials.gov

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)

PHASE4CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

HIV Infection

Interventions

DRUG

Tenofovir, Emtricitabine, Lopinavir/r

Combination drug

DRUG

Tenofovir, Emtricitabine, Raltegravir

Combination drug

Trial Locations (1)

08036

Hospital Clínic of Barcelona, Barcelona

All Listed Sponsors

lead

Hospital Clinic of Barcelona

OTHER

NCT01576731 - Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) | Biotech Hunter | Biotech Hunter